Retinalamin
Research OnlyAlso known as: Retinal peptide complex, Eye peptide, Retina bioregulator
A peptide complex extracted from bovine or porcine retinal tissue, developed by Russian scientist Vladimir Khavinson for ophthalmologic applications. Registered as a drug in Russia for retinal dystrophy and age-related macular degeneration. Very limited Western validation exists.
Research Statistics
Russian bioregulator (Khavinson lab); all research from Russian ophthalmology institutes. No independent Western clinical trials. Mechanism proposed as retinal peptide bioregulation but lacks Western mechanistic validation.
Research Dossier
Overview
What is Retinalamin and what does the research say?
Mechanism of Action
The proposed mechanisms of Retinalamin are based primarily on Russian research. As a tissue-derived peptide complex rather than a single defined molecule, precise mechanistic characterization is limited.
How It Works (Simplified)
Retinalamin is theorized to support retinal function through multiple pathways related to its tissue origin:
Stimulates retinal pigment epithelium (RPE) cell function and may promote regenerative processes in damaged retinal tissue.
May influence local growth factors and cytokines that support photoreceptor and retinal ganglion cell survival.
Proposed to improve retinal blood flow and metabolic processes, supporting oxygen and nutrient delivery to retinal cells.
Animal studies suggest protection against programmed cell death in retinal ganglion cells and photoreceptors under stress conditions.
Scientific Pathways
Tissue Regeneration Pathway (Retinal Support)
Retinalamin Peptides → RPE Cell Membrane Interactions → Gene Expression Modulation
↓
Growth Factor Synthesis ↑ → Photoreceptor Support
↓
Improved Retinal Function (proposed)Neuroprotective Pathway (Cell Survival)
Retinalamin → Mitochondrial Stabilization → Reduced Oxidative Stress
↓
Anti-Apoptotic Signaling (Bcl-2 ↑, Bax ↓)
↓
Retinal Ganglion Cell Preservation (proposed)Key Research Context: All mechanistic research originates from Russian institutes. The exact composition of retinalamin varies by batch as it is a tissue extract, making precise molecular characterization impossible. This is a fundamental limitation compared to synthetic peptides with defined sequences.
Important Limitations
- Undefined composition: Not a single molecule but a peptide mixture; exact active components unknown
- No Western validation: All clinical studies are Russian; no independent replication
- Study quality issues: Most trials are open-label without placebo controls or adequate blinding
- Tissue-derived concerns: Animal tissue extracts carry theoretical risks of contamination and immunogenicity
- Administration barriers: Requires injection by trained medical personnel
- Regulatory status: Not approved outside Russia/CIS; considered experimental elsewhere
- Mechanism uncertainty: Without defined sequence, molecular mechanisms remain speculative
Evidence-Chained Benefits
Evidence-Chained Benefits
Research findings linked to mechanisms and clinical outcomes
What to Expect
Timeline based on observations from published studies. Individual responses may vary.
Initial treatment phase. In Russian clinical protocols, patients typically receive 5-10 daily injections. Some studies report subjective improvement in visual comfort within the first week of treatment.
Measurable changes in electrophysiological parameters (ERG) reported by week 2-3 in some studies. Visual acuity improvements may begin to manifest. Full injection course typically completed.
Peak effect period following completion of treatment course. Russian studies measure outcomes at 4-8 weeks post-treatment. Improvements in visual field sensitivity and contrast sensitivity documented.
Long-term maintenance phase. Russian protocols often recommend repeat courses every 6-12 months. Duration of effect varies by condition and individual response. No long-term safety data from controlled studies.
Research-Based Observations
This timeline reflects observations from published clinical and preclinical studies. Individual responses may vary significantly. This is not a guarantee of effects or a dosing schedule. Consult qualified healthcare providers for personalized guidance.
Quality Checklist
Visual indicators to help evaluate Retinalamin product quality
Good Signs (6 indicators)
Warning Signs (5 indicators)
Bad Signs (6 indicators)
For Research Evaluation Only
These quality indicators are general guidelines based on typical peptide characteristics. Professional laboratory testing (HPLC, mass spectrometry) provides definitive quality verification. This checklist is for initial visual evaluation only.
Peptide Interactions
Known and theoretical interactions when combining Retinalamin with other peptides. Based on published research and mechanistic considerations.
Cortexin
CompatibleBoth tissue-derived Khavinson peptide complexes - cortexin for neurological support, retinalamin for retinal function. Often used together in Russian clinical practice for optic nerve conditions.
Epithalon
CompatibleDifferent targets within Khavinson bioregulator framework - epithalon for systemic longevity via telomerase, retinalamin for tissue-specific retinal support.
Thymalin
CompatibleBoth tissue-derived peptide complexes from Khavinson research. Thymalin provides immune modulation while retinalamin targets retinal tissue. No known contraindications.
Semax
CompatibleBoth Russian peptides with neuroprotective properties - Semax via BDNF for general neuroprotection, retinalamin specifically for retinal neurons.
Selank
CompatibleDifferent therapeutic targets - Selank for anxiolytic and nootropic effects, retinalamin for retinal tissue support. No known interactions.
Research Note: Interaction data is based on published literature, mechanistic understanding, and theoretical considerations. Most peptide combinations lack direct clinical study. This information is for educational purposes only and does not constitute medical advice. Always consult qualified healthcare providers.
References
Key Studies Cited
Full reference list available on request. All citations link to PubMed for verification.
Methodology Note
This dossier synthesizes available evidence from peer-reviewed literature, regulatory documents, and clinical trial registries. Evidence strength ratings follow a modified GRADE approach.
For complete methodology details, see our Methodology page.
Important Disclaimer
This dossier is for educational purposes only and does not constitute medical advice. Always consult a qualified healthcare provider before making health decisions.
Get Research Alerts
New dossiers and major study summaries delivered to your inbox. Evidence-graded, citation-backed research you can trust.
No spam. Unsubscribe anytime.
Compare Retinalamin
Related Peptides
225Ac-DOTA-LM3
Actinium-225-DOTA-LM3, 225Ac-DOTA-JR11, Alpha-PRRT +1 more
An alpha-emitting radiolabeled somatostatin receptor antagonist for peptide receptor radionuclide therapy (PRRT) in neuroendocrine tumors. Unlike conventional beta-emitting Lu-177 therapies and SSTR agonists, 225Ac-DOTA-LM3 combines the higher cell-killing power of alpha particles with antagonist binding for enhanced tumor targeting. Clinical stage investigational therapy showing promise in Lu-177-refractory patients.
Bronchogen
AEDL, Ala-Glu-Asp-Leu, Bronchial tetrapeptide +1 more
A synthetic tetrapeptide (Ala-Glu-Asp-Leu) developed by Russian scientist Vladimir Khavinson for bronchial and respiratory tissue support. Claimed to modulate bronchial epithelium gene expression and provide respiratory protective effects. No Western clinical validation; all evidence from Russian bioregulator research.
BT5528
Bicycle Toxin Conjugate 5528, EphA2-BTC
A first-in-class Bicycle Toxin Conjugate (BTC) targeting EphA2-expressing tumors, developed by Bicycle Therapeutics. Combines a constrained bicyclic peptide targeting moiety with the cytotoxic payload MMAE. Phase 1/2 dose expansion ongoing with 67% ORR reported in EphA2-positive urothelial cancer patients.
Cardiogen
AED, Ala-Glu-Asp, Cardiac tripeptide
A synthetic tripeptide (Ala-Glu-Asp) developed by Russian scientist Vladimir Khavinson for cardiac tissue support. Claimed to target cardiomyocyte gene expression and provide cardioprotective effects. No Western clinical validation exists; evidence limited to Russian preclinical and observational studies.
Chonluten
EDG-GI, Glu-Asp-Gly (GI), GI tract tripeptide +1 more
A synthetic tripeptide (Glu-Asp-Gly) developed by Vladimir Khavinson for gastrointestinal tissue support. Shares the same amino acid sequence as Kristagen but is marketed for digestive system rather than immune function. Limited to Russian studies with no Western validation or clinical trials.
EVX-01
EVX01, Evaxion EVX-01, AI-Immunology Neoantigen Vaccine
A personalized neoantigen peptide vaccine developed by Evaxion Biotech using AI-driven neoantigen prediction. Phase 1 data in melanoma showed 67% overall response rate when combined with anti-PD-1 therapy, with neoantigen-specific T-cell responses detected in all patients. Distinct from mRNA-based approaches like mRNA-4157.